Valneva SE (VALN) Assets Average (2022 - 2026)
Valneva SE (VALN) posted quarterly Assets Average of $438.6 million for Q1 2026, down 21.52% year-on-year from $558.9 million in Q1 2025, and down 9.0% on a QoQ basis from $482.0 million in Q4 2025.
Valneva SE (VALN) Assets Average (2022 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Assets Average for 5 consecutive years, with $438.6 million the latest figure, recorded in Q1 2026.
- Quarterly Assets Average fell 21.52% year-over-year to $438.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $438.6 million (down 21.52% YoY) and the FY2025 annual result came in at $511.4 million, down 6.38% from the prior year.
- Assets Average declined to $438.6 million in Q1 2026 per VALN's latest filing, from $482.0 million in the prior quarter.
- Over the last five years, Assets Average for VALN reached as high as $907.6 million in Q1 2022 and fell as low as $438.6 million in Q1 2026.
- A 5-year average of $623.7 million and a median of $559.4 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average dropped 25.68% — and 2024, when it grew 3.68%.
- Year by year, Assets Average stood at $750.7 million in 2022, then fell by 25.68% to $557.9 million in 2023, then rose by 3.68% to $578.4 million in 2024, then retreated by 16.68% to $482.0 million in 2025, then slipped by 9.0% to $438.6 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $438.6 million, $482.0 million, and $523.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 65.01 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.37 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 41.64 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.30 Bn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | 438.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 438.60 Mn |
| Dec 31, 2025 | 481.96 Mn |
| Sep 30, 2025 | 523.94 Mn |
| Jun 30, 2025 | 543.30 Mn |
| Mar 31, 2025 | 558.89 Mn |
| Dec 31, 2024 | 578.45 Mn |
| Sep 30, 2024 | 559.41 Mn |
| Jun 30, 2024 | 551.57 Mn |
| Mar 31, 2024 | 547.86 Mn |
| Dec 31, 2023 | 557.94 Mn |
| Sep 30, 2023 | 604.89 Mn |
| Jun 30, 2023 | 644.41 Mn |
| Mar 31, 2023 | 689.23 Mn |
| Dec 31, 2022 | 750.72 Mn |
| Sep 30, 2022 | 809.76 Mn |
| Jun 30, 2022 | 855.07 Mn |
| Mar 31, 2022 | 907.55 Mn |